Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2003

View Archived Issues

Novel therapeutic strategies for diabetes

Janssen describes novel inhibitors of TNF-alpha and/or IL-12 production

Arpida prepares and tests novel antibacterial agents

Aventis presents new MCH receptor modulators with anorectic activity

Dual NK1 antagonists/5-HT reuptake inhibitors and their use reported by GSK

New glucokinase activators in early development at AstraZeneca

Oxytocin agonists with utility in erectile dysfunction claimed by Ferring

GSK scientists identify new Lp-PLA2 inhibitors for use in atherosclerosis therapy

Novel DNA protein kinase inhibitors discovered by Cancer Research Technology

New beta3-adrenoceptor agonists discovered at Lilly

Zonagen terminates Lavipharm merger agreement

Xenogen and Morphochem to develop novel compounds against bacterial biofilms

DOV Pharmaceutical reports on past four months

Hexvix improves treatment of bladder cancer patients

E.U. Erbitux filing remains on track following data review

FDA advisory committee sets May date for review of Xolair BLA

IL-10 gene therapy prolongs islet graft survival and inhibits diabetes recurrence in mice

Bay-41-2272 as an alternative to nitrate therapy for CHF and related disorders

CVT-4325, a new FOX inhibitor, induces a metabolic shift to glucose utilization in rat hearts

Selective inhibitor of Itk designed at BMS as lead compound for T-cell-mediated disorders

New series with strong activity against PTP1B presented at ACS meeting

Nonimidazole H3 receptor antagonist A-320436 characterized in preclinical experiments

Regeneron and Novartis to codevelop IL-1 Trap for RA

Johnson & Johnson completes acquisition of 3-DP

Normalization of lipid profiles in hypercholesterolemic rabbits on JTT-705

Chronic YM-598 restores myocardial energy metabolism to normal in CHF rats

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...